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Contrast-enhanced MR cholangiography
with Gd-EOB-DTPA in patients with liver
cirrhosis: visualization of the biliary ducts
in comparison with patients with normal liver
parenchyma
Abstract The purpose of this study
was to assess the quality of biliary
duct visualization using Gd-
EOB-DTPA-enhanced magnetic reso-
nance cholangiography (EOB-MRC)
in patients with liver cirrhosis. Forty
adult patients with liver cirrhosis (cir-
rhosis group) and 20 adult individuals
with normal liver parenchyma (control
group) underwent EOB-MRC using
T1-weighted GRE imaging up to
180 min after Gd-EOB-DTPA admin-
istration. Two observers assessed the
visualization of each biliary structure
and the overall anatomical visualiza-
tion of the biliary tree. Child-Pugh,
MELD score and laboratory findings
were compared. The grade of visual-
ization for each evaluated biliary
structure was statistically different in
the two groups (P=0.004 to <0.001).
The overall EOB-MRC quality was
rated as sufficient for anatomical
visualization of the biliary tree in all
individuals of the control group
20 min after Gd-EOB-DTPA applica-
tion, but in only 16/40 patients (40%)
of the cirrhosis group within 30 min
after application. Analysis of the ROC
curves revealed that the cut-off values,
for non-sufficient visualization of the
biliary tree 20 min after Gd-
EOB-DTPA application, were MELD
scores ≥11 and total serum bilirubin
levels ≥30 μmol/l. Consecutively,
EOB-MRC in patients with liver cir-
rhosis resulted in a decreased or even
non-visualization of the biliary tree in
a substantial percentage of patients.
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Introduction
Contrast-enhanced magnetic resonance cholangiography
(MRC) using hepatobiliary contrast agents, in combina-
tion with T1-weighted two-dimensional (2D) or three-
dimensional (3D) gradient-echo (GRE) sequences, is
considered an alternative to conventional techniques for
the evaluation of the biliary tree [1, 2]. Recent studies have
shown that contrast-enhanced MRC is particularly useful
for the evaluation of biliary tract abnormalities in healthy
individuals (e.g., potential living liver donors), and in
patients suspected to have a biliary leak [1, 3–5]. Although
contrast-enhanced MRC is increasingly used by radiolo-
gists, there is paucity of data in the literature with regard to
the degree and extent of biliary excretion of hepatobiliary
contrast agents. To the best of our knowledge, all of these
studies were performed in patients with healthy liver
parenchyma and normal liver function [1, 6–9]. However,
since hepatobiliary contrast agents are excreted into the
bile ducts by a cellular process at the level of the
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hepatocyte, it might be hypothesized that the degree of
biliary excretion of the contrast agent is dependent on liver
function. This is of particular interest in patients with liver
cirrhosis who have impaired liver function.
Hence, the purpose of this study was to assess the quality
of visualization of the biliary ducts in Gd-EOB-DTPA
(gadoxetic acid)-enhanced MRC (EOB-MRC) with liver
cirrhosis patients and in comparison with individuals with
normal liver parenchyma and normal liver function.
Materials and methods
The study was approved by the local ethics committee and
written informed consent was obtained from all participat-
ing patients before their MR examination.
Patients
During a 15-month period (October 2005 to December
2006), 40 consecutive adult patients (nine female, 31 male,
mean age 52.9 years) with liver cirrhosis were included in
this prospective study (cirrhosis group). Patients were
included only if the liver cirrhosis was histologically
proven by biopsy and if the patients had no previous
hepatic or biliary surgery with exception of cholecystec-
tomy. None of the patients had undergone transarterial
chemoembolization, percutaneous ethanol injections,
radiofrequency ablation, or implantation of a transjugular
intrahepatic stent-shunt. All patients were referred to our
institution for work-up before a possible liver transplant
and fulfilled the Milan criteria (one nodule <5 cm, or two to
three nodules all <3 cm, and without macroscopic vascular
invasion) [10]. Exclusion criteria were age under 18 years,
general contraindications for MR examinations (i.e., car-
diac pacemakers, neurostimulators, ferromagnetic im-
plants, etc.), pregnancy, breast feeding, contraindications
for the use of contrast agents containing gadolinium (i.e.,
known previous reactions, etc.), application of another
liver-specific or gadolinium-containing contrast agent in
the last 2 weeks, creatinine clearance below 30 ml/min, and
simultaneous participation in another study.
The underlying causes of liver cirrhosis were hepatitis C
(13 patients), hepatitis B (seven patients), alcohol abuse
(seven patients), primary biliary sclerosing cholangitis
(five patients), autoimmune hepatitis (two patients), cryp-
togenic cirrhosis (three patients), and primary biliary
cirrhosis (one patient). In two patients the reason for the
liver cirrhosis was unknown. Cirrhosis was classified as
Child-Pugh class A in 19 patients, Child-Pugh class B in 15
patients, and Child-Pugh class C in six patients.
The cirrhosis group was compared to a control group of
20 prospectively consecutive adult individuals (five fe-
male, 15 male, mean age 44.8 years) with normal liver
function, which were referred for clinical reasons during
the study period. Individuals were included in the control
group only if there was no clinical history, clinical signs,
imaging findings, or laboratory parameters of liver dys-
function (i.e., normal serum values of blood coagulation
parameters, liver enzymes, and total bilirubin). Patients
with focal liver lesions were included as long as they had
≤4 lesions, which were each ≤3 cm in diameter. Exclusion
criteria were the same as stated for the cirrhosis group. The
indications for liver MR imaging were evaluation of
potential living liver donors, follow-up examinations of
focal liver lesions, and assessment of unclear focal liver
lesions previously detected by other imaging modalities.
The focal liver lesions proven by either histology or
imaging follow-up were hemangiomas (seven individuals),
focal nodular hyperplasia (five individuals), cysts (five
individuals), metastases (five individuals), focal steatosis
or sparing (three individuals), and adenomas (one indivi-
dual). In one individual no focal or diffuse liver pathology
was found.
MR imaging
All individuals underwent MR imaging of the liver using a
1.5-Tesla MR system (Signa EchoSpeed EXCITE HD; GE
Healthcare, Milwaukee, Wis., USA). For signal reception
in all examinations an eight-channel anteroposterior
phased-array surface coil was placed around the individual
and covered the entire liver.
Imaging protocols for both of the groups included
unenhanced sequences (coronal single-shot fast spin-echo
(SSFSE), transaxial T2-weighted fast spin-echo (FSE), in-
and out-of-phase gradient-echo (GRE) sequences), dynam-
ic GRE sequences in the arterial, portal-venous and
extracellular phase, as well as delayed sequences (see
below). Each individual received an intravenous bolus
injection of gadolinium-ethoxybenzyl-dietylenetriamine
pentaacetic acid (Gd-EOB-DTPA; gadoxetic acid, Primo-
vist, Bayer Schering Pharma, Berlin, Germany) as contrast
agent at a dose of 25 μmol/kg body weight at a flow rate of
2 ml/s, followed by a 20-ml saline flush. The dynamic as
well as the delayed imaging was performed using a fat-
suppressed 3D T1-weighted GRE sequence using parallel
imaging (LAVA EFGRE ASSET breathhold: TR/
TE=3.1 ms/1.4 ms; flip angle,15°; field of view, 42×
42 cm; matrix, 384×256, interpolated to 512×512;
thickness, 4 mm; overlap 2 mm, ASSET acceleration,
2.0). Whereas the dynamic GRE imaging was performed in
the transaxial plane, the delayed imaging (so-called MRC)
was performed at different time points up to 180 min after
bolus application of Gd-EOB-DTPA in the transaxial as
well as in the coronal planes. All individuals of both groups
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had delayed MR imaging at 10, 20, and 30 min after bolus
application of Gd-EOB-DTPA. Additional delayed MR
imaging at 60, 120, and 180 min after bolus application of
Gd-EOB-DTPAwere performed only if the visualization of
the biliary ducts was not sufficient for anatomical diagnosis
within 30 min after application of Gd-EOB-DTPA (defi-
nition of the criteria see below). The attending radiologist
made the decision whether additional delayed MR imaging
at 60, 120, and 180 min had to be performed. This
radiologist was not involved in the image analysis of the
study.
Image analysis
Two experienced radiologists (D.W. and F.T.C.T., with 12
and 5 years of experience in abdominal MR imaging,
respectively), blinded to all clinical and radiological data,
evaluated all MR images of the delayed phase of imaging
(MRC) in random order and in consensus. Randomization
was performed with regard to patients, cirrhosis versus
control group, and the different time points when imaging
was performed. For imaging evaluation, the transaxial as
well as coronal planes of the MRC for each time point were
available. The source images as well as the reformatted
images [maximum intensity projections (MIPs)] were
evaluated electronically on an interactive workstation
(Advantage Windows Workstation 4.2; GE Medical
Systems Europe, Buc, France). The readers themselves
performed the MIPs.
The readers were asked to evaluate all image sets (i.e.,
EOB-MRC of each time point) with regard to the grade
of visualization of the bile ducts. For the purpose of the
study, the biliary tree was divided into the following
different anatomical parts: the common bile duct, cystic
duct, gallbladder, common hepatic duct, right and left
hepatic duct and second order division ducts. The grade
of visualization of the different parts of the biliary tree
was assessed separately at each time point using the
following three-point scale: grade 0, no visualization;
grade 1, poor visualization; grade 2, good visualization.
Grade 0 or 1 was applied if no or only little contrast
media could be identified in the examined portion of the
biliary tree. Bile ducts classified as grade 2 were
completely and sufficiently filled by the intrabiliary
contrast agent.
In addition to the grading of visualization of the
individual anatomical structures of the biliary tree, an
overall rating taking into account the entire biliary tract was
performed. Visualization of the biliary tree was deemed
sufficient for anatomical diagnosis if visualization of the
common bile duct, common hepatic duct, and left and right
hepatic ducts was rated as good (grade 2) at the same time
point.
Comparison with liver-function parameters
Patients’ charts were reviewed and various blood serum
parameters were recorded as long as they were available and
not older than 1 week before or after MR imaging. Since all
included patients were referred from our liver transplant unit
and imaging was performed for work-up prior to a possible
liver transplant, laboratory investigationswere performed for
clinical reasons. The following serum parameters were
recorded: platelet count, quick prothrombin time (PT),
international normalized ratio (INR), partial thromboplastin
time (PTT), total bilirubin, protein, albumin, ceruloplasmin,
aspartate aminotransferase (ASAT), alanine aminotransfer-
ase (ALAT), gamma-glutamyl transpeptidase (GGT), alka-
line phosphatase (AP), transferrin, ferritin, and creatinine. In
addition, the Child-Pugh class and the model for end-stage
liver disease (MELD) score of each patient were determined.
The MELD score is based on the formula: 9.57 ×
loge[creatinine (mg/dl)] + 3.78 × loge[total bilirubin
(mg/dl)] + 11.2 × loge(INR) + 6.43 and calculated using an
online worksheet available over the internet at http://www.
mayo clinic.org/gi-rst/mayomodel5.html. Although calcula-
tion of MELD score is only meaningful in patients with
impaired liver function, for the purpose of this study we
calculated this score also for patients with normal liver
function (so-called theoretical MELD score).
The blood serum parameters as well as the Child-Pugh
class and the MELD score were compared with the grade of
visualization of the bile ducts in both groups at each time
point.
Statistics
Statistical analysis was performed using SPSS 12.0.1 for
Windows (SPSS, Chicago, USA). Comparisons between
the grade of visualization of the bile ducts in both groups
and the various liver function parameters were performed
by using the Mann-Whitney test. Cut-off values for single
liver function parameters were determined by means of
receiver-operating characteristic (ROC) curves. Fisher’s
exact test (for overall anatomical visualization of the biliary
tree) and the Mann-Whitney test (for liver function
parameters) were used to compare the two patient groups.
Mann-Whitney test with exact P values and Bonferroni
correction for multiple testing (for three examined time
points) was performed to compare the frequency distribu-
tion of the grade of visualization of each of the evaluated
biliary structures of the biliary tree 10, 20 and 30 min after
contrast application in the two patient groups, so statistical
significance was accepted if P<0.0167 (0.05/3). For all
other tests statistical significance was accepted if P<0.05.
ROC curves and graphs were plotted usingMedCalc 9.3.0.0
for Windows (MedCalc Software, Mariakerke, Belgium).
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Results
There were no statistically significant differences in terms
of age and gender between the cirrhosis and the control
group.
Liver-function parameters
The mean values ± standard deviation of the serum
parameters in both patients groups are listed in Table 1.
The serum parameters of the control group were all within
a normal range. There were significant differences between
both groups regarding platelet count (P<0.001), quick PT
(P<0.001), INR (P<0.001), PTT (P=0.032), total bilirubin
(P<0.001), albumin (P=0.001), ASAT (P<0.001), ALAT
(P=0.007), GGT (P=0.02), and AP (P=0.001).
The mean MELD score ± standard deviation in the
cirrhosis group was 12.4±5.86. The theoretical mean
MELD score ± standard deviation in the control group was
6.3±0.57. This difference was highly statistically signif-
icant (P<0.001).
Visualization of the bile ducts
The frequency distribution of the grade of visualization of
each evaluated part of the biliary tree, in both groups 10,
20, and 30 min after intravenous administration of Gd-
EOB-DTPA, is displayed in Table 2.
The frequency distribution of the grade of visualization
was statistically significantly different for each of the
evaluated biliary structures 10, 20 and 30 min after
administration of contrast medium, when comparing the
cirrhosis with the control group (P=0.004 to <0.001). The
visualization of each of the evaluated biliary structures
was graded with a lower score in the cirrhosis group
compared with the control group.
The frequency distribution of the grade of visualization
of each of the evaluated parts of the biliary tree in the 24
cirrhotic patients, where additional imaging was required
after 60, 120 and 180 min of application of Gd-EOB-
DTPA, is displayed in Table 3.
Only 16/40 patients (40%) from the cirrhosis group
reached sufficient visualization of the biliary tree for
anatomical diagnosis within 30 min after application of
Gd-EOB-DTPA (Fig. 1), whereas the visualization of the
biliary tree was rated sufficient in 20/20 individuals
(100%) from the control group after 20 min and in
14/20 individuals (70%) after 30 min (Fig. 2). The
24/40 patients (60%) from the cirrhosis group with
insufficient overall visualization of the biliary tree for
anatomical diagnosis within 30 min after contrast
administration were followed up to 180 min. Only five
of these 24 patients (21%) had a sufficient visualization
of the biliary tree at a later time point (in two patients
60 min and in three patients 180 min after contrast
application). In the remaining 19/24 patients (79%), the
visualization of the biliary system remained insufficient
for anatomical diagnosis, even up to 180 min after
contrast administration (Figs. 3, 4). This means that in
19/40 patients (48%) sufficient visualization of the
biliary tree for anatomical diagnosis was not reached
even up to 180 min after i.v. administration of Gd-EOB-
DTPA.
Table 3 Overview of the frequency distribution of the image
quality score 60, 120 and 180 min after administration of Gd-EOB-
DTPA in patients with liver cirrhosis and non-sufficient visualiza-
tion of the biliary tree, within the 30 minutes after administration of
Gd-EOB-DTPA
Time after intravenous administration of Gd-EOB-DTPA
60 min (n=24) 120 min (n=24) 180 min (n=24)
Grade of visualizationa 0 1 2 0 1 2 0 1 2
Common bile duct 10(42) 12(50) 2(8) 3(13) 18(75) 3(13) 6(25) 12(50) 6(25)
Cystic ductb 13(59) 9(41) 0(0) 15(68) 5(23) 2(9) 17(77) 2(9) 3(14)
Gallbladderb 17(77) 5(23) 0(0) 15(68) 7(32) 0(0) 14(64) 8(36) 0(0)
Common hepatic duct 3(13) 13(54) 8(33) 1(4) 16(67) 7(29) 1(4) 15(63) 8(63)
Right hepatic duct 4(17) 15(63) 4(17) 5(21) 10(42) 9(38) 5(21) 12(50) 7(29)
Left hepatic duct 7(29) 13(54) 4(17) 5(21) 14(58) 5(21) 10(42) 8(33) 6(25)
Second order division ducts 15(63) 9(38) 0(0) 10(42) 4(17) 5(21) 15(63) 6(25) 3(13)
Numbers represent individuals; numbers in parentheses represent percentages
aGrade 0 = no visualization; grade 1 = low visualization; grade 2 = good visualization
bIn 2/24 patients (8%) of the cirrhosis group, a cholecystectomy had been performed before MR imaging
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The effect of liver function on biliary visualization
In the cirrhosis group, patients with insufficient biliary tree
visualization for anatomical diagnosis 20 and 30 min after
contrast application had a significant higher INR (P=
0.015/0.041), PTT (P=0.005/0.046), and total bilirubin
(P≤0.001) compared with patients with sufficient biliary
tree visualitzation. The other tested laboratory findings did
not show statistically significant difference. Analysis of the
ROC curves (Figs. 5 and 6) revealed a cut-off value for
total bilirubin ≥30 μmol/l / ≥1.8 mg/dl (sensitivity 0.75,
specificity 0.93, area under the curve 0.85) for insufficient
visualization of the biliary tree for anatomical diagnosis
20 min after contrast application. In the cirrhosis group,
patients with insufficient biliary tree visualization for
anatomical diagnosis 20 and 30 minutes after contrast
application had a significant higher MELD score (P≤
0.001) compared to patients with sufficient biliary tree
Fig. 1a–f EOB-MRC on a 51-year-old man with histologically
proven hepatitis C liver cirrhosis (MELD score 10, total bilirubin
20 μmol/l / 1.2 mg/dl). Fat-suppressed 3D T1-weighted GRE
images (3.1/1.4, 15° flip angle) in the coronal (a–c) and transaxial
plane (d–f) demonstrate the excretion of Gd-EOB-DTPA over time.
After 10 min (a, d) no enhancement (grade 0) of any of the
evaluated biliary structures is visible. Following 20 (b, e) and 30
min (c, f) the common bile duct (small arrow), common hepatic duct
(large arrow), left and right hepatic ducts (arrowheads) are well
visualized (grade 2). Hence, the visualization of the biliary tree was
rated as sufficient for anatomical diagnosis
Fig. 2a–c EOB-MRC on a 34-year-old man with normal liver
function. Fat-suppressed 3D T1-weighted GRE images (3.1/1.4, 15°
flip angle) in the coronal plane show a sufficient overall visualiza-
tion of the biliary tree 10 (a), 20 (b), and 30 (c) min after application
of Gd-EOB-DTPA. This means that the visualization of the common
bile duct (small arrow), common hepatic duct (large arrow) and the
left and right hepatic ducts (arrowheads) was rated as good (grade 2)
at the same time point
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visualization. Analysis of the ROC curves (Figs. 5 and 7),
revealed a cut-off MELD score of ≥11 (sensitivity 0.79,
specificity 0.86, area under the curve 0.87) for insufficient
visualization of the biliary tree for anatomical diagnosis
20 min after contrast application.
In the cirrhosis group, the comparison between the
degree of visualization of the biliary tree and the Child-
Pugh class revealed no statistical significance.
Discussion
Recent studies have shown the utility of contrast-
enhanced MRC especially in visualizing non-dilatated
bile ducts (e.g., in living liver donors) and biliary leaks
[4, 5, 11]. Currently, three different hepatobiliary
contrast agents are available for contrast-enhanced
MRC: mangafodipir trisodium (Mn-DPDP; Teslascan;
GE Healthcare, Oslo, Norway), gadobenate dimeglumine
(Gd-BOPTA; MultiHance, Bracco Imaging, Milan, Italy),
and gadolinium-ethoxybenzyl-diethylenetriamine pentaace-
tic acid (Gd-EOB-DTPA, gadoxetic acid; Primovist, Bayer
Schering Pharma, Berlin, Germany).
When Gd-EOB-DTPA is injected intravenously, the
contrast agent is incorporated into the hepatocytes by an
anionic transport system after the vascular phase. For the
intracellular transport of Gd-EOB-DTPA glutathione-
S-transferase has been identified as transport protein [7].
The excretion into the biliary tract is also mediated by the
glutathione-S-transferase transport system. It has been
demonstrated that both bilirubin as well as Gd-EOB-DTPA
have a high affinity for the same hepatocellular receptor
glutathione-S-transferase [7]. Analysis of pharmacokinetic
results in a clinical phase-I trial, demonstrated that Gd-
Fig. 3a–h EOB-MRC on a 42-year-old male patient with histo-
logically proven liver cirrhosis (MELD score 12, total bilirubin
68 μmol/l / 4mg/dl). Fat-suppressed 3D T1-weighted GRE images
(3.1/1.4, 15° flip angle) in the coronal (a–d) and transaxial plane (e–
h) were obtained over time following administration of Gd-EOB-
DTPA. Thirty minutes after Gd-EOB-DTPA administration no
enhancement of the biliary structures is noted neither in the coronal
(a) nor in the transaxial plane (e). After 60 (b, f), 120 (c, g) and 180
(d, h) min only the common hepatic duct (arrow) is visualized
(grade 2, at 120 min; grade 1, at 60 and 180 min). There is no
enhancement of other biliary structures at any of the time points,
resulting in a non-sufficient overall visualization of the biliary tree at
all time points
Fig. 4 Coronal (a) and transaxial (b) fat-suppressed 3D T1-
weighted GRE images (3.1/1.4, 15° flip angle) obtained 180 min
following Gd-EOB-DTPA administration in a 55-year-old male
patient with histologically proven liver cirrhosis and decreased liver
function (MELD score 18, total bilirubin 158 μmol/l / 9.2 mg/dl).
No enhancement of the biliary structures is noted at this time point
as well as at the earlier time points (not shown)
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EOB-DTPA was eliminated non-metabolized in approxi-
mately equal proportions by hepatobiliary excretion and
glomerular filtration [9].
In an in-vivo phase-I clinical evaluation performed in 16
healthy volunteers receiving different doses of Gd-
EOB-DTPA, Bollow et al. [7] showed an intense signal
enhancement of the common bile duct beginning 5–16 min
after contrast application. Carlos et al. [8] showed that a
20-min delay after Gd-EOB-DTPA administration was
sufficient for adequate biliary visualization in 16 patients
with known hepatic masses. Hamm et al. [9] demonstrated
common bile duct enhancement within 10 min after
injection of Gd-EOB-DTPA. All these studies were
performed in patients with functionally unimpaired liver
parenchyma. Our results of the control group are in
accordance with these above-mentioned studies. In all
individuals of the control group, the quality of the EOB-
MRC was rated sufficient for anatomical diagnosis after
20 min.
To the best of our knowledge, this study has shown for
the first time that the time elapsed between intravenous
administration of Gd-EOB-DTPA and visualization of the
biliary ducts is different in a substantial percentage of
patients with liver cirrhosis compared with the visualiza-
tion of the bile ducts in non-cirrhotic liver parenchyma.
Only 16/40 patients of the cirrhosis group (40%) showed
an overall sufficient MRC image quality for anatomical
diagnosis within 30 min of contrast application. Even if the
Fig. 5 ROC curves illustrate the relationship between the visual-
ization of the biliary tree 20 min after Gd-EOB-DTPA application
and the MELD score (area under the curve 0.87), as well as the total
serum bilirubin (area under the curve 0.85)
Fig. 6 Graphs illustrating the sensitivity and specificity of the
corresponding bilirubin value according to a good biliary tree
visualization. Note the decrease of the sensitivity at corresponding
bilirubin levels ≥30 μmol/l
Fig. 7 Graphs illustrating the sensitivity and specificity of the
corresponding MELD score according to a good biliary tree
visualization. Based on the highest possible sensitivity and speci-
ficity, a cut-off MELD score ≥11 was defined above which effective
biliary visualization should not be expected
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window between Gd-EOB-DTPA injection and acquisition
of MR imaging was prolonged up to 180 min, overall
visualization of the biliary tree could be obtained only in
21/40 patients (53%). The reason for this difference in
dynamics and extent of biliary excretion of Gd-EOB-DTPA
in cirrhotic and in non-cirrhotic livers ismost likely due to the
differences in liver function. Since the transport into the bile
ducts of both Gd-EOB-DTPA and (conjugated and unconju-
gated) bilirubin is mediated by glutathione-S-transferase
proteins, this may explain these findings. In addition, in
advanced liver cirrhosis the number of functioning hepa-
tocytes is reduced, thus causing the capacity for the excretion
of bilirubin andGd-EOB-DTPA to be reduced. In these cases
most of Gd-EOB-DTPA is probably excreted via the kidneys
because the renal and hepatic excretions are competing
excretion mechanisms [9].
In our study, comparison of various laboratory findings
and the MELD score representing liver function and the
grade of visualization of the biliary ducts revealed
statistical significance. In cirrhotic patients with a MELD
score ≥11 and/or a total serum bilirubin level ≥30 μmol/l
(≥1.8 mg/dl), the likelihood to achieve a contrast-enhanced
MRC sufficient for displaying the biliary tree morphology
is low. This means, for practical purposes, that EOB-MRC
can not be recommended in these patients.
On the other hand, a diminished liver function can be
suspected in patients with a reduced or lacking visualiza-
tion of the biliary tree 20 and 30 min after application of
Gd-EOB-DTPA (in the absence of a biliary obstruction).
This is supported by the study of Ryeom et al. [12] who
were able to evaluate liver function quantitatively with Gd-
EOB-DTPA-enhanced MR imaging calculating the Gd-
EOB-DTPA hepatic extraction fraction.
The fact that we could not find a statistical significance
comparing the Child-Pugh class and the visualization of the
biliary tree may be explained by the fact that the Child-
Pugh class is less precise and more examiner-dependent
compared with the MELD score (subjective quantification
of ascites and encephalopathy in the Child-Pugh classifi-
cation). Additionally, recent publications emphasize the
superiority of the MELD scale compared with the Child-
Pugh classification in predicting the 3-month mortality
among patients with chronic liver disease [13, 14].
We acknowledge the following limitations. In our study
we included only patients with liver cirrhosis and impaired
liver function, but we had no patients with liver dysfunc-
tion in the absence of a cirrhotic liver. However, patients
with liver cirrhosis represent the majority of patients with
liver dysfunction in a clinical setting. Another limitation
might be related to the fact that the number of patients in
both groups was relatively small and that we had no
histological proof that the liver parenchyma of the
individuals in the control group was normal. Because we
performed a consensus read-out, the lack of the degree of
interobserver agreement may represent another study
limitation.
In this study we focused on the ability of Gd-EOB-DTPA
to visualize the biliary tree for morphological information.
However, we did not appreciate the property of Gd-
EOB-DTPA to provide functional information.
In conclusion, the present study has shown that patients
with liver cirrhosis have delayed excretion of the hepato-
biliary contrast agent Gd-EOB-DTPA compared to in-
dividuals with normal liver parenchyma. This results in an
inferior or even insufficient enhancement of the biliary tree
in a substantial percentage of cirrhotic patients.
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